Provided by Tiger Trade Technology Pte. Ltd.

Neurosense Therapeutics Ltd

0.3472
+0.01524.58%
Post-market: 0.3399-0.0073-2.10%19:49 EDT
Volume:233.42K
Turnover:78.11K
Market Cap:13.11M
PE:-0.80
High:0.3491
Open:0.3450
Low:0.3300
Close:0.3320
52wk High:1.33
52wk Low:0.2500
Shares:37.77M
Float Shares:25.85M
Volume Ratio:0.18
T/O Rate:0.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4366
EPS(LYR):-0.4366
ROE:-2174.98%
ROA:-247.30%
PB:-8.41
PE(LYR):-0.80

Loading ...

NeuroSense CMO Ferenc Tracik steps down, effective April 27

Reuters
·
Apr 24

NeuroSense wins Brazil patent for PrimeC composition, extending protection to 2042

Reuters
·
Apr 06

NeuroSense gets Nasdaq notice for breaching $1 minimum bid price requirement

Reuters
·
Apr 03

Neurosense Therapeutics Ltd. (NRSN) Receives a Buy from Roth MKM

TIPRANKS
·
Apr 02

NeuroSense files Form 3 as CFO Or Eisenberg reports beneficial ownership

Reuters
·
Apr 02

NeuroSense FY25 net loss widens 9% to USD 11.1 million

Reuters
·
Apr 01

NeuroSense Therapeutics director Revital Mandil-Levin files initial beneficial ownership statement

Reuters
·
Apr 01

Israel's NeuroSense Therapeutics 2025 net loss widens as expenses rise

Reuters
·
Mar 31

BRIEF-NeuroSense Therapeutics FY EPS USD -0.44

Reuters
·
Mar 31

Neurosense Therapeutics FY Operating Income USD -11.085 Million

THOMSON REUTERS
·
Mar 31

Neurosense Therapeutics FY EPS USD -0.44

THOMSON REUTERS
·
Mar 31

Press Release: NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update

Dow Jones
·
Mar 31

NeuroSense files Form 3 for CTO Niva Russek-Blum initial beneficial ownership

Reuters
·
Mar 31

NeuroSense CEO Alon Ben-Noon files initial beneficial ownership statement

Reuters
·
Mar 30

NeuroSense to report clinical and biomarker results from Alzheimer’s study in coming weeks

Reuters
·
Mar 24

NeuroSense Therapeutics Director Cary J. Claiborne Files Initial Beneficial Ownership Statement

Reuters
·
Mar 19

NeuroSense Therapeutics Ltd. Director Roy Golan Files Initial Beneficial Ownership Statement

Reuters
·
Mar 19

NeuroSense Therapeutics Ltd. Director Mark Leuchtenberger Files Initial Beneficial Ownership Statement

Reuters
·
Mar 19

NeuroSense Therapeutics Ltd. files Form 3 initial beneficial ownership statement for General Manager Hagit Binder

Reuters
·
Mar 19

NeuroSense to Present PrimeC Phase 2b PARADIGM Data at AD/PD 2026 Conference

Reuters
·
Mar 18